New Chlamydia Vaccine Moves onto Next Stage of Clinical Trials

Chlamydia is a disease that affects millions of people around the world. There hasn’t been a vaccine for it until now. The first chlamydia vaccine is currently being tested out on people. After a successful first round of tests, the vaccine is progressing to the next round. This is good news to at-risk men and women and could prevent millions of new infections.


A Possible End to a Global Disease

Chlamydia causes around 131 million new infections globally each year. In the U.S. alone, the U.S. Centers for Disease Control and Prevention estimates that there were 1.7 million cases of chlamydia. The disease affects both men and women and is the most common sexually transmitted disease caused by bacteria in the U.S.

It has been difficult to come out with a vaccine against the bacterium Chlamydia trachomatis, resulting in high numbers of infections. Additionally, many infections are never reported and very often, infected people do not experience any symptoms.

New Hope After Initial Clinical Trial

The first chlamydia vaccine has produced promising results in the first test. Two versions of the vaccines and a placebo were randomly given to around 36 healthy women. The tests proved that both versions of the vaccine are safe and produced an immune response in the participants. In the group of participants given a placebo, there was no immune response. The findings of the study are reported in Lancet Infectious Diseases.

The commentary of the study was coauthored by pediatric infectious disease specialist at the University of North Carolina School of Medicine in Chapel Hill, Toni Darville. He believes the results from the initial tests are very promising to end the harmful effects of this disease. Also, chlamydia can go undetected, it can also result in long-term health complications in women.


Editor's Picks

reset password

Back to
log in